The Role of Cholesterol in the Pathogenesis of NASH

Trends in Endocrinology and Metabolism

Volumn 27, Issue 2, 2016, Pages 84-95

  Ioannou, George N ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholesterol crystals; Fibrosis; Inflammation; NAFLD; NASH

Indexed keywords

CHOLESTEROL; CRYOPYRIN; EZETIMIBE; FAT DROPLET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; MEMBRANE PROTEIN;

CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CRYSTALLIZATION; DISEASE COURSE; HEREDITY; HOMEOSTASIS; HUMAN; KUPFFER CELL; LIPOTOXICITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEMBRANE FLUIDITY; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STELLATE CELL; ANIMAL; CELL MEMBRANE; CHEMISTRY; GENETICS; LIPID METABOLISM; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY;

ANIMALS; CELL MEMBRANE; CHOLESTEROL; CRYSTALLIZATION; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIPID METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84958942979     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.11.008     Document Type: Review

References (101)

1. Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
2. Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
3. Williams C.D., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
4. Beste L.A., et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 2015, 149:1471-1482.
5. Afzali A., et al. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012, 18:29-37.
6. Matteoni C.A., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
7. Bugianesi E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
8. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl. 1):S5-S10.
9. Wree A., et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:627-636.
10. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
11. Yamaguchi K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
12. Wouters K., et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010, 584:1001-1005.
13. Scorletti E., Byrne C.D. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu. Rev. Nutr. 2013, 33:231-248.
14. Musso G., et al. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52:175-191.
15. Arguello G., et al. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim. Biophys. Acta 2015, 1852:1765-1778.
16. Hendrikx T., et al. Lysosomal cholesterol accumulation: driver on the road to inflammation during atherosclerosis and non-alcoholic steatohepatitis. Obes. Rev. 2014, 15:424-433.
17. Kumashiro N., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16381-16385.
18. Chaurasia B., Summers S.A. Ceramides - lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 2015, 26:538-550.
19. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J. Clin. Invest. 2002, 110:905-911.
20. Su W., et al. Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:11437-11442.
21. Greenberg A.S., Coleman R.A. Expanding roles for lipid droplets. Trends Endocrinol. Metab. 2011, 22:195-196.
22. Greenberg A.S., et al. The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Invest. 2011, 121:2102-2110.
23. Tauchi-Sato K., et al. The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J. Biol. Chem. 2002, 277:44507-44512.
24. Thiam A.R., et al. The biophysics and cell biology of lipid droplets. Nat. Rev. Mol. Cell Biol. 2013, 14:775-786.
25. Hsieh K., et al. Perilipin family members preferentially sequester to either triacylglycerol-specific or cholesteryl-ester-specific intracellular lipid storage droplets. J. Cell Sci. 2012, 125:4067-4076.
26. Dietschy J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 2009, 390:287-293.
27. Radhakrishnan A., et al. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 2008, 8:512-521.
28. Lambert G., et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 2003, 278:2563-2570.
29. Min H.K., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012, 15:665-674.
30. Simonen P., et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J. Hepatol. 2011, 54:153-159.
31. Caballero F., et al. Enhanced free cholesterol SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50:789-796.
32. Savard C., et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013, 57:81-92.
33. Subramanian S., et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 2011, 52:1626-1635.
34. Van Rooyen D.M., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011, 141:1393-1403.
35. Ioannou G.N., et al. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009, 50:175-184.
36. Ioannou G.N., et al. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 2013, 54:1326-1334.
37. Ioannou G.N., et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. J. Lipid Res. 2015, 56:277-285.
38. Zheng S., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 2008, 584:118-124.
39. Yoneda M., et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol. Res. 2010, 40:613-621.
40. Puri P., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
41. Musso G., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
42. Yasutake K., et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 2009, 44:471-477.
43. Dongiovanni P., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 2015, 63:705-712.
44. Athyros V.G., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
45. Athyros V.G., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 2006, 22:873-883.
46. Foster T., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol. 2011, 106:71-77.
47. Nelson A., et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J. Clin. Gastroenterol. 2009, 43:990-994.
48. Park H., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol. 2011, 46:101-107.
49. Chan D.C., et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139.
50. Takeshita Y., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014, 57:878-890.
51. Loomba R., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology 2014, 61:1239-1250.
52. Romeo S., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
53. Speliotes E.K., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
54. Rotman Y., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
55. Pirazzi C., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148 M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 2012, 57:1276-1282.
56. Huang Y., et al. Expression and characterization of a PNPLA3 protein isoform (I148 M) associated with nonalcoholic fatty liver disease. J. Biol. Chem. 2011, 286:37085-37093.
57. Dongiovanni P., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015, 61:506-514.
58. Cefalu A.B., et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2021-2025.
59. Chalasani N., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1567-1576.
60. Burton B.K., et al. A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N. Engl. J. Med. 2015, 373:1010-1020.
61. Montero J., et al. Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochim. Biophys. Acta 2010, 1797:1217-1224.
62. Mari M., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006, 4:185-198.
63. Li L., et al. Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways. J. Biol. Chem. 2011, 286:17809-17820.
64. Hager L., et al. Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice. J. Biol. Chem. 2012, 287:20755-20768.
65. Legry V., et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. Clin. Sci. (Lond.) 2014, 127:507-518.
66. Hodges B.D., Wu C.C. Proteomic insights into an expanded cellular role for cytoplasmic lipid droplets. J. Lipid Res. 2010, 51:262-273.
67. Arrese E.L., et al. Lipid droplets as signaling platforms linking metabolic and cellular functions. Lipid Insights 2014, 7:7-16.
68. Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 2015, 15:104-116.
69. Brown M.S., Goldstein J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11041-11048.
70. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vas. Biol. 2009, 29:431-438.
71. Kunjathoor V.V., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 2002, 277:49982-49988.
72. Jerome W.G., et al. Lysosomal lipid accumulation from oxidized low density lipoprotein is correlated with hypertrophy of the Golgi apparatus and trans-Golgi network. J. Lipid Res. 1998, 39:1362-1371.
73. Li W., et al. Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation. Arterioscler. Thromb. Vas. Biol. 1998, 18:177-184.
74. Bieghs V., et al. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 2012, 56:894-903.
75. Bieghs V., et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int. 2013, 33:1056-1061.
76. Bieghs V., et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 2010, 138:2477-2486.
77. Bieghs V., et al. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS ONE 2012, 7:e34378.
78. Bieghs V., et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 2013, 144:167-178. e1.
79. Liu B., et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res. 2010, 51:933-944.
80. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet. Med. 2007, 24:1-6.
81. Varsano N., et al. Formation of 3D cholesterol crystals from 2D nucleation sites in lipid bilayer membranes: implications for atherosclerosis. J. Am. Chem. Soc. 2015, 137:1601-1607.
82. Feldstein A.E., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
83. Wieckowska A., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
84. Haka A.S., et al. Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated lipoproteins. Mol. Biol. Cell 2009, 20:4932-4940.
85. Dixon L.J., et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab. Invest. 2012, 92:713-723.
86. Dixon L.J., et al. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS ONE 2013, 8:e56100.
87. Wree A., et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014, 59:898-910.
88. Szabo G., Iracheta-Vellve A. Inflammasome activation in the liver: focus on alcoholic and non-alcoholic steatohepatitis. Clin. Res. Hepatol. Gastroenterol. 2015, 39(Suppl 1):S18-S23.
89. Duewell P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
90. Rajamaki K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 2010, 5:e11765.
91. Cassel S.L., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9035-9040.
92. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
93. Miao E.A., et al. Caspase-1-induced pyroptotic cell death. Immunol. Rev. 2011, 243:206-214.
94. Bergsbaken T., et al. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7:99-109.
95. Rockey D.C., et al. Fibrosis-a common pathway to organ injury and failure. N. Engl. J. Med. 2015, 372:1138-1149.
96. Wallace M.C., et al. Emerging and disease-specific mechanisms of hepatic stellate cell activation. Semin. Liver Dis. 2015, 35:107-118.
97. Teratani T., et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012, 142:152-164.
98. Tomita K., et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014, 59:154-169.
99. Musso G., et al. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 2011, 94:1033-1042.
100. Kang Q., Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab. Invest. 2009, 89:1275-1290.
101. Tomita K., et al. Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J. Hepatol. 2014, 61:98-106.